Picture of Canopy Growth logo

WEED — Canopy Growth News Story

0.000.00%
ca flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapNeutral

Canada's Canopy Growth Q1 revenue slightly misses estimates

Canada's Canopy Growth Q1 revenue slightly misses estimates


Overview

  • Canada cannabis producer's fiscal Q1 net revenue rose 13% yr/yr, slightly missed analyst expectations

  • Adjusted EBITDA loss for fiscal Q1 narrowed by 59% yr/yr, driven by revenue growth and cost savings

  • Adjusted gross margin improved to 31% from 25% yr/yr


Outlook

  • Company anticipates further financial improvements, especially in H2 FY2027, as MTL Cannabis integration completes

  • Canopy Growth expects growth in each end market driven by clear strategies and increased high-quality flower supply

  • Company sees expanded revenue opportunities and meaningful synergies from MTL Cannabis acquisition


Result Drivers

  • MTL CANNABIS ACQUISITION - Co said acquisition led to increased supply of high-quality flower and expanded revenue opportunities, supporting growth in Canada medical and adult-use cannabis

  • SEGMENT SALES GROWTH - Co reported net revenue growth in Canada medical cannabis (22%), Canada adult-use cannabis (10%), international markets cannabis (10%), and Storz & Bickel (6%)

  • COST RATIONALIZATION - Storz & Bickel gross margin rose due to cost rationalization and recovery of certain U.S. tariffs


Company press release: ID:nBw8cfx25a


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q1 Net Revenue

Slight Miss*

C$81.20 mln

C$81.63 mln (5 Analysts)

Q1 Adjusted EBITDA

-C$3.20 mln

Q1 Gross Margin

27.00%

*Applies to a deviation of less than 1%; not applicable for per-share numbers.


Analyst Coverage

  • The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

  • Wall Street's median 12-month price target for Canopy Growth Corporation is C$1.60, about 20.3% above its August 6 closing price of C$1.33


Reuters Recommended Reads

  • Aug 5 - Aurora Cannabis Q1 revenue falls 9% on Canadian reimbursement cuts

  • Aug 6 - Canada's Cronos Group Q2 revenue beats estimates on higher cannabis flower sales

  • Aug 6 - Canada's TerrAscend Q2 revenue beats estimates on retail strength


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Canopy Growth

See all news